- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03038178
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open-label study of efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI), in addition to a standard multi-drug antibiotic therapy in accordance with the 2007 ATS/ IDSA guidelines, in patients with Mycobacterium abscessus lung disease. The multi-drug therapy is determined at the discretion of the Investigator. After screening, all eligible patients will enter the trial and will receive LAI 590 mg once daily for 12 months. If deemed necessary by the investigator, dose may be adjusted from a minimum of three times per week up to daily, in cases of adverse events relating to tolerability.
All patients who enter the study will have subsequent study visits at Months 1,2,4,6,9, at End-of-Study or Month 12, and at 1 and 3 months post study drug discontinuation. At each visit (including screening), review of concomitant medications, review of adverse events, and physical exam, will be performed. Chest CT scan will be performed at baseline, 6 months, and 12 months, unless a chest CT scan has already been performed within 6 months on this time point. The 6 minute walk test and QOL-B-NTM will be performed at baseline, 6 months, 12 months, and 3 months post study drug discontinuation. All patients will have inducted sputum collected at each study visit, and patients will self-collect expectorated sputum during intervening monthly time-points until study completion to determine changes in mycobacterial smear and culture status.
Unscheduled visits will occur as needed should subjects' symptoms worsen between visits.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Texas
-
Tyler, Texas, United States, 75708
- University of Texas Health Science Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 12 years and older
- Diagnosis of M. abscessus, including all subspecies, abscessus, bolleti, and massiliense lung disease according to the 2007 ATS/IDSA criteria
- Both newly diagnosed and currently on treatment or previously treated patients will be included
- Culture positive (either sputum or bronchoscopy) for M. abscessus at time of screening
- Willingness to adhere to a treatment regimen, study visits, and study procedures during the course of the study.
- Ability to produce at approximately 3.0 mL of sputum or be willing to undergo an induction that produces approximately 3.0 mL of sputum for culture collection
- Female of childbearing potential agrees to practice an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD)
- Written informed consent or assent obtained from the patient, parent or legal guardian prior to the performance of any study related procedures
Exclusion Criteria:
- Active pulmonary tuberculosis requiring treatment at screening
- Treatment with inhaled or intravenous Amikacin within 14 days prior to baseline
- Known hypersensitivity to aminoglycosides
- Aspartate aminotransferase or alanine aminotransferase ≥ 3 times the upper limit of normal or total bilirubin ≥ 2 times the upper limit of normal (ULN) at screening
- Current addiction to alcohol or illicit drug abuse
- Any condition which in the opinion of the Investigator interferes with ability to adhere to study requirements
- Primary immunodeficiency syndromes and acquired immunodeficiency syndromes (e.g., HIV-positive patients regardless of CD4 counts)
- Absolute neutrophil count ≤500/μL at Screening
- Significant (as determined by the investigator) hearing loss, vestibular dysfunction, neuromuscular weakness or a diagnosis of myasthenia gravis, where the potential risk of aminoglycoside toxicity outweighs the potential benefit
- Serum creatinine >2 times ULN at Screening
- History of lung transplantation
- Any condition that, in the judgment of the Investigator, would compromise the ability of the subject to complete the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LAI plus multi-drug regimen
once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
|
Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline sputum culture at 12 months
Time Frame: Sputum examined for culture change from Baseline at 12 months
|
Sputum examined for culture change from Baseline at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline 6-minute Walk Test at 6 months
Time Frame: 6-minute Walk Test results examined for change from Baseline at 6 months
|
6-minute Walk Test results examined for change from Baseline at 6 months
|
Change from Baseline 6-minute Walk Test at 12 months
Time Frame: 6-minute Walk Test results examined for change from Baseline at 12 months
|
6-minute Walk Test results examined for change from Baseline at 12 months
|
Change from End of Treatment (EOT) sputum culture at 3 months post EOT
Time Frame: Sputum examined for culture change from EOT at 3 months post EOT
|
Sputum examined for culture change from EOT at 3 months post EOT
|
Number of Hospitalizations for pulmonary exacerbations
Time Frame: Number of Hospitalizations for pulmonary exacerbations that occur between Baseline and 12 months
|
Number of Hospitalizations for pulmonary exacerbations that occur between Baseline and 12 months
|
Number of Adverse Events
Time Frame: Number of Patient-reported and Investigator-reported Adverse Events at 12 months
|
Number of Patient-reported and Investigator-reported Adverse Events at 12 months
|
Number of subjects discontinuing study drug due to Adverse Event
Time Frame: Number of subjects who discontinue study drug before 12 months due to Adverse Event will be examined at 12 months
|
Number of subjects who discontinue study drug before 12 months due to Adverse Event will be examined at 12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline reported nontuberculous mycobacterium (NTM) symptoms at End of Treatment (EOT)
Time Frame: Patient-reported NTM symptoms examined for change from Baseline at EOT (12 months)
|
Patient-reported NTM symptoms examined for change from Baseline at EOT (12 months)
|
Change from Baseline Chest CT at End of Treatment (EOT)
Time Frame: CT scan examined for change from Baseline at EOT (12 months)
|
CT scan examined for change from Baseline at EOT (12 months)
|
Change from Baseline body weight at End of Treatment (EOT)
Time Frame: body weight of patient examined for change from Baseline at EOT (12 months)
|
body weight of patient examined for change from Baseline at EOT (12 months)
|
Change from Baseline Body Mass Index (BMI) at End of Treatment (EOT)
Time Frame: BMI of patient examined for change from Baseline at EOT (12 months)
|
BMI of patient examined for change from Baseline at EOT (12 months)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAI/INS-IIR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mycobacterium Infections, Nontuberculous
-
Kevin WinthropPatient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaboratorsRecruitingMycobacterium Avium Complex | Nontuberculous Mycobacterium InfectionUnited States, Canada
-
The University of Texas Health Science Center at...AbbottCompletedMycobacterium Avium Complex | Nontuberculous MycobacteriaUnited States
-
University of Illinois at ChicagoTerminatedAtypical Mycobacterium Infections | Nontuberculous Mycobacterial DiseaseUnited States
-
Inje UniversityMinistry of Science and ICTRecruitingLatent Tuberculosis | Tuberculosis | Nontuberculous Mycobacterium InfectionKorea, Republic of, Indonesia
-
The University of Texas Health Science Center at...PfizerCompletedNontuberculous Mycobacterial InfectionsUnited States
-
Oregon Health and Science UniversityUniversity Health Network, Toronto; New York University; NTM Info & Research,...RecruitingNontuberculous Mycobacterial Lung Disease | Nontuberculous Mycobacterium InfectionUnited States, Canada
-
LigaChem Biosciences, Inc.Active, not recruitingMycobacterium Abscessus Infection | Nontuberculous Mycobacterium InfectionKorea, Republic of
-
Paratek Pharmaceuticals IncActive, not recruitingMycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary InfectionUnited States
-
Radboud University Medical CenterRecruitingNontuberculous Mycobacterial Lung Disease | Mycobacterium Avium ComplexNetherlands
-
Seoul National University HospitalUnknownWhole Genome Sequencing | Nontuberculous Mycobacterium InfectionKorea, Republic of
Clinical Trials on LAI plus multi-drug regimen
-
Insmed IncorporatedCompletedNTM Lung Infection Due to MAC
-
Xiaodong SunShanghai Zhongshan Hospital; Eye & ENT Hospital of Fudan UniversityUnknownPolypoidal Choroidal VasculopathyChina
-
Integrative Skin Science and ResearchCodex Beauty CorporationNot yet recruitingAcne VulgarisUnited States
-
Karo Pharma ABCompletedBacterial VaginosisPoland
-
Pacira Pharmaceuticals, IncCompletedPain Management | Elective Cesarean SectionUnited States
-
José Raimundo Araujo de AzevedoNot yet recruitingMulti Drug Resistant Bacteria
-
MDI HealthHadassah Medical OrganizationCompletedPolypharmacy PatientsIsrael
-
Janssen Infectious Diseases BVBACompletedTuberculosisSouth Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
-
Henan University of Traditional Chinese MedicineRecruitingChronic Obstructive Pulmonary DiseaseChina
-
Hopital LariboisièreCompletedBeta Lactam Resistant Bacterial Infection (Disorder)France